Company Encyclopedia
View More
name
TMSP
600671.SH
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, hard capsules, and other health foods. It is also involved in the sale of menthol and peppermint oil raw materials, Chinese medicine formulas, Chinese medicine pieces, Chinese herbal medicine slices, fresh herbs, etc.; and provision of professional medical services, such as decoction, delivery, slicing, and powdering, as well as Chinese medicine diagnosis and treatment services. In addition, the company engages in software development, remote health management, commercial complex management, food, Internet information businesses, etc.
3.038 T
600671.SHMarket value -Rank by Market Cap -/-

Financial Score

31/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking74/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE66.28%A
    • Profit Margin13.18%B
    • Gross Margin55.29%B
  • Growth ScoreA
    • Revenue YoY56.88%A
    • Net Profit YoY328.42%A
    • Total Assets YoY17.30%A
    • Net Assets YoY66.87%A
  • Cash ScoreB
    • Cash Flow Margin758.84%B
    • OCF YoY56.88%A
  • Operating ScoreB
    • Turnover0.63B
  • Debt ScoreE
    • Gearing Ratio78.06%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The traditional Chinese medicine concept continues to rise, WBDE hits the limit up, Honz, TMSP, Zhenbao Island, JI LIN AO DONG and others follow suit

    Zhitong·
    SZ
    002082
    +0.22%
    SZ
    300086
    +1.92%
    SH
    600671
    -0.69%
    Zhitong·
    SZ
    002082
    +0.22%
    SZ
    300086
    +1.92%
    SH
    600671
    -0.69%

    TMSP's subsidiary received the drug re-registration approval notice

    According to the Zhitong Finance APP, TMSP announced that its wholly-owned subsidiary Huangshan TMSP Co., Ltd. (referred to as "Huangshan TMSP") recently received the approval notice for re-registration of several drugs, including Liuwei Dihuang Wan, issued by the Anhui Provincial Drug Administration. The acquisition of the above-mentioned drug re-registration approval notice ensures the stability and continuity of the company's drug production and sales qualifications, which has positive significance for the company's subsequent production, sales, and promotion

    Zhitong·
    SH
    600671
    -0.69%
    Zhitong·
    SH
    600671
    -0.69%

    TMSP: Net profit of 10.2478 million yuan in the first half of 2025, turning from loss to profit

    TMSP announced that in the first half of 2025, operating revenue reached 104 million yuan, a year-on-year increase of 73.97%. Net profit was 10.2478 million yuan, compared to a loss of 18.5007 million yuan in the same period last year

    Zhitong·
    SH
    600671
    -0.69%
    Zhitong·
    SH
    600671
    -0.69%

    Some traditional Chinese medicine stocks saw their net profits double year-on-year in the first half of the year

    As of now, 19 listed companies have released their semi-annual reports for 2025, among which companies like DRTG, JI LIN AO DONG, and BUCHANG PHARMA have seen their net profits double year-on-year. DRTG expects its net profit for the first half of the year to reach between 1.84 billion and 2 billion yuan, a year-on-year increase of 180% to 204%, mainly due to profits from equity sales. TMSP has turned losses into profits, with an overall improvement in profitability. The stock hit the daily limit today, with well-known speculative funds net buying 9.5309 million yuan

    Zhitong·
    SH
    600671
    -0.69%
    SH
    600329
    -0.93%
    SZ
    000623
    -0.25%
    Zhitong·
    SH
    600671
    -0.69%
    SH
    600329
    -0.93%
    SZ
    000623
    -0.25%

    Ophthalmology concept experiences a volatile rebound, TMSP hits the limit up

    The ophthalmology concept experienced a volatile rebound, with TMSP hitting the limit up, followed by gains in Xingqi Pharmaceutical, Laimei Pharmaceutical, Nosseland, Daheng Technology, Guanhao Biological, and Doctor Glasses

    Zhitong·
    SZ
    300573
    +1.76%
    SH
    600671
    -0.69%
    Zhitong·
    SZ
    300573
    +1.76%
    SH
    600671
    -0.69%
    © 2025 Longbridge｜Disclaimer